Osiris Therapeutics

Osiris, Mesoblast enter agreement

Friday, October 11, 2013

Osiris Therapeutics, a stem cell company, has entered into an agreement with a wholly-owned subsidiary of Mesoblast for the sale of Osiris’ culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal, in a transaction worth up to $100 million. Additionally, Osiris will receive royalty payments on sales of Prochymal and other products utilizing the acquired ceMSC technology.

[Read More]